Thomas Lackner, PharmD, CGP, FASCP
Professor, Department of Experimental and Clinical Pharmacology
College of Pharmacy
University of Minnesota
David R. Staskin, MD
Associate Professor - Urology
Tufts University School of Medicine
Caritas-St. Elizabeth's Medical Center
Pharmacists: 1.5 Contact Hours (0.15 CEUs)
NOTE: This activity was presented on November 18, 2009, in conjunction with ASCP's 40th Annual Meeting and Exhibition.
Participants who received credit for attending either the live presentation or participating in the webcast on that date are not eligible to receive credit for this online activity.
Overactive bladder (OAB) is a chronic, debilitating condition that affects approximately 33 million Americans. The symptoms of OAB—urinary incontinence (UI), urgency, and urinary frequency—often lead to further medical and psychological problems and can have a devastating impact on quality of life. UI affects people of all ages; however, it is most prevalent in older adults, especially in skilled nursing facilities. Estimates of the prevalence of UI in skilled nursing facility residents range from 43% to 77%. OAB remains under-recognized and undertreated due to patient reluctance to seek medical care and clinician failure to proactively ask questions to identify OAB. In addition, patients who are diagnosed and treated often fail to comply with treatment and thus do not receive the full benefits of therapy. The management of OAB in older patients can be particularly challenging because of the added complexity of polypharmacy and comorbidities. Senior care pharmacists play an important role in improving outcomes in older adults with OAB. With an expanding range of treatment options, pharmacists are in an excellent position to optimize pharmaceutical care of patients with OAB by utilizing the latest clinical evidence to recommend the most appropriate treatment plans.
Patient-Centered Approaches to Improve the Management of Overactive Bladder in Older Adults will define symptoms related to overactive bladder and differentiate among other common voiding dysfunctions to identify patients who suffer from the condition. Through an interactive case study, pharmacists will learn about the effectiveness and safety of pharmacologic agents and ways to implement optimal therapeutic strategies that improve patient adherence and outcomes.
• Welcome and Introductions
• Pathophysiology of OAB
• Assessment and Diagnosis
• Clinical case: Identifying undiagnosed OAB
• Nonpharmacologic and Pharmacologic Management of OAB
• Strategies to Improve Patient Adherence with Therapeutic Regimens
• Question-and-Answer Session Target Audience
This educational activity is designed to meet the needs of pharmacists and other health care providers interested in the diagnosis, prevention and treatment of overactive bladder in older adults.
Upon completion of this application-based educational activity, the participant should be able to:
Implement strategies to identify patients who “silently” suffer from overactive bladder symptoms.
Define symptoms related to overactive bladder while differentiating among other voiding dysfunction conditions.
Evaluate the effectiveness, safety, and tolerability profiles of pharmacologic agents available for the treatment of overactive bladder.
Establish effective strategies and interventions to improve patient adherence to overactive bladder therapeutic regimens.
In accordance with the standards set forth by the Accreditation Council for Pharmacy Education, it is the policy of the American Society of Consultant Pharmacists to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any relevant financial relationship or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with a relevant financial relationship or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker¹s interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Thomas Lackner, PharmD, CGP, FASCP has no relevant financial relationships to disclose.
David R. Staskin, MD has no relevant financial relationships to disclose.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
Pharmacists:The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity, ACPE Universal Activity #203-999-09-103-H01-P, has been assigned 1.5 Contact Hours (0.15 CEUs).
Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing pharmacy education credit. Credit will be awarded for a score of 70% or better, and a statement may be printed immediately after passing the post-test.
Partial credit cannot be awarded.
There is no fee to participate in this educational activity.
Commercial Support Statements
This activity is supported through an independent educational grant from Astellas Pharma Global Development, Inc.